Abstract
Polymyalgia rheumatica is a disease characterized by systemic inflammation of the proximal muscles and pain in the hips and shoulders, but when this disease occurs contemporaneously with malignancy, there is a possibility of it being a paraneoplastic syndrome. With the advent of immunotherapies to treat various cancers, immune-related adverse events from these therapies are recognized as de novo findings or as flares of an underlying existing rheumatic disease. In this report, we present a case of polymyalgia rheumatica presenting as a paraneoplastic syndrome that was exacerbated during therapy with immune checkpoint inhibitors for recurrent melanoma.
Original language | English (US) |
---|---|
Pages (from-to) | 124-125 |
Number of pages | 2 |
Journal | Baylor University Medical Center Proceedings |
Volume | 34 |
Issue number | 1 |
DOIs | |
State | Published - 2021 |
Keywords
- Immune checkpoint inhibitor
- immune-related adverse event
- ipilimumab
- melanoma
- nivolumab
- paraneoplastic syndrome
- polymyalgia rheumatica
ASJC Scopus subject areas
- Medicine(all)